The Association Between Psoriasis and Cardiovascular Comorbidity: A Narrative Review
- 1Department of Dermatology, College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
- 2King Abdullah International Medical Research Center, Riyadh, Saudi Arabia
Abstract
Psoriasis is a chronic immune-mediated inflammatory disease that extends beyond the skin and is increasingly recognized as a systemic disorder associated with multiple cardiometabolic comorbidities. Growing evidence indicates that patients with psoriasis, particularly those with moderate to severe disease, have an increased risk of cardiovascular morbidity and mortality, including myocardial infarction, stroke, atherosclerotic cardiovascular disease, and cardiovascular death. This narrative review summarizes the current evidence linking psoriasis with cardiovascular comorbidity, with emphasis on disease severity, systemic inflammation, psoriatic arthritis, pediatric psoriasis, and cardiovascular risk factors. The available literature suggests that mild psoriasis may not consistently increase cardiovascular event risk, whereas moderate to severe psoriasis is more frequently associated with adverse cardiovascular outcomes. Pediatric psoriasis has also been linked with obesity, hypertension, diabetes, arrhythmia, and other cardiovascular comorbidities. Shared inflammatory pathways, endothelial dysfunction, metabolic disturbances, and traditional cardiovascular risk factors appear to contribute to this association. These findings support the need to approach psoriasis as a systemic inflammatory disease requiring early cardiovascular risk assessment, lifestyle modification, and multidisciplinary management.
Related
- Exploring Dietary Supplements for Psoriasis Management: A Narrative Review
- Food-Derived Substances and Edible Chinese Medicinal Materials in Psoriasis Management: Potential, Evidence, and Perspectives-A Narrative Review.
- Tumor necrosis factor inhibitors and cardiovascular outcomes in adults with moderate-to-severe plaque psoriasis: a systematic review and meta-analysis☆
- Protocol for a cohort study of comprehensive intervention of psoriasis and diabetes comorbidity prevention and control using traditional Chinese medicine of blood-activating and stasis-dissolving method
- Molecular Biomarkers Linking Psoriasis and Cardiovascular Disease: Current Evidence and Clinical Perspectives
BibTeX
@article{almohideb2026association,
title = {{The Association Between Psoriasis and Cardiovascular Comorbidity: A Narrative Review}},
author = {Mohammad Almohideb},
journal = {Galen Medical Journal},
year = {2026},
month = aug,
doi = {10.31661/gmj.v15i.4156},
url = {https://doi.org/10.31661/gmj.v15i.4156},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - The Association Between Psoriasis and Cardiovascular Comorbidity: A Narrative Review
AU - Mohammad Almohideb
PY - 2026
DA - 2026/08/27
JO - Galen Medical Journal
DO - 10.31661/gmj.v15i.4156
UR - https://doi.org/10.31661/gmj.v15i.4156
AB - Psoriasis is a chronic immune-mediated inflammatory disease that extends beyond the skin and is increasingly recognized as a systemic disorder associated with multiple cardiometabolic comorbidities. Growing evidence indicates that patients with psoriasis, particularly those with moderate to severe disease, have an increased risk of cardiovascular morbidity and mortality, including myocardial infarction, stroke, atherosclerotic cardiovascular disease, and cardiovascular death. This narrative review summarizes the current evidence linking psoriasis with cardiovascular comorbidity, with emphasis on disease severity, systemic inflammation, psoriatic arthritis, pediatric psoriasis, and cardiovascular risk factors. The available literature suggests that mild psoriasis may not consistently increase cardiovascular event risk, whereas moderate to severe psoriasis is more frequently associated with adverse cardiovascular outcomes. Pediatric psoriasis has also been linked with obesity, hypertension, diabetes, arrhythmia, and other cardiovascular comorbidities. Shared inflammatory pathways, endothelial dysfunction, metabolic disturbances, and traditional cardiovascular risk factors appear to contribute to this association. These findings support the need to approach psoriasis as a systemic inflammatory disease requiring early cardiovascular risk assessment, lifestyle modification, and multidisciplinary management.
SN - 2588-2767
SN - 2322-2379
ER -